Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis

Table 2 Pancreatic DNA synthesis, pancreatic blood flow, plasma lipase activity, and the levels of IL-1β and IL-10 in rats treated with various doses of pioglitazone alone or in combination with cerulein infused s.c. to induce pancreatitis

	Pancreatic DNA synthesis (dpm/μg DNA)	Pancreatic blood flow (% of control)	Plasma lipase activity (U/L)	Plasma IL-1β (pg/mL)	Plasma IL-10 (pg/mL)
Control	58.8±1.6	100±2.0	57.0±6.0	70.3±4.2	67.0±5.0
Pioglitazone 10 mg/kg	61.3±1.9	98.9±1.7	62.3±5.6	69.7±3.9	66.9±4.1
Pioglitazone 20 mg/kg	60.9±2.2	99.6±2.1	59.2±6.7	74.2±5.5	72.7±5.1
Pioglitazone 50 mg/kg	61.6±1.1	101.5±1.7	60.5±4.5	68.2±4.9	73.0±3.0
Pioglitazone 100 mg/kg	57.4±2.1	97.6±2.4	71.8±6.9	76.8±5.4	71.9±5.1
Cerulein	33.8±1.4a	60.9±2.5a	400.3±10.6a	212.0±8.6a	79.2±3.5
Pioglitazone 10 mg/kg+cerulean	37.6±2.8a	66.2±2.1a	372.1±12.1a	198.4±5.7a	73.1±3.8
Pioglitazone 20 mg/kg+cerulean	41.6±1.7a,c	69.3±1.5a,c	322.4±9.6a,c	153.2±6.2a,c	81.6±7.2
Pioglitazone 50 mg/kg+cerulean	45.9±1.7a,c	79.2±2.2a,c	288.3±18.0a,c	131.3±7.2a,c	75.1±3.0
Pioglitazone 100 mg/kg+cerulean	39.6±2.3a	65.1±2.3a	269.3±13.9a	129.3±6.9a	64.6±3.2

^aP<0.05 vs control, ^cP<0.05 vs cerulein alone.